side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Austria

With over 150 international specialist lawyers across CMS and the support of the Life Sciences Asia-Pacific Network (LAN), we understand the scientific and commercial as well as the legal imperatives affecting your life sciences & healthcare business. We work with and have established long-term relationships with the top 100 life sciences & healthcare companies in the areas of pharmaceuticals, medical devices, biotechnology, agriculture and food, including the top 20 global pharmaceutical companies and nine out of the top ten global medical device companies.

Our experts, many of whom have worked in-house in your sector, have developed a shared capability in the areas of pharmaceuticals, biotechnology, medical devices and diagnostics. With active memberships in major industry associations we help shape the legal frameworks impacting the life sciences & healthcare sector.

We regularly advise our clients on their day-to-day operational needs such as support with advertisement and promotion of medicine, public sector procurement, pricing and reimbursement, patent enforcement, commercial and clinical trial agreements as well as regulatory advice and compliance. Equally, when you need life sciences & healthcare specialist advice for strategic agreements, planning a corporate transaction or embarking on litigation (whether product liability or otherwise), we have a team that is well versed in the industry issues to help you.

Read more Read less

Choose area

    Medical Law

    Legal questions are becoming increasingly relevant in the medical field, driven in part by the intended austerity and restructuring mandates of recent years. How do health care institutions comply with the multitude of legal requirements and yet still remain commercially viable? This is just one of the many challenges that we can help you meet.

    Read more
    CMS Start up ini­ti­at­ive

    Feed

    Show only
    Gabriela Staber
    17/05/2018
    Dis­tri­bu­tion and mar­ket­ing of drugs in Aus­tria: over­view
    A Q&A guide to dis­tri­bu­tion and mar­ket­ing of drugs...
    24/08/2018
    Gov­ern­ment Is­sues Brexit Tech­nic­al No­tice for Life Sci­ences
    On 23 Au­gust 2018, the UK Gov­ern­ment (the "Gov­ern­ment") is­sued the first wave of its tech­nic­al pa­pers de­signed to provide guid­ance to com­pan­ies to help pre­pare for a "No Deal" Brexit. In this scen­ario, there will be no "trans­ition peri­od" but rather the UK.
    15/01/2018
    Lifes­ci­ences Ex­pert Gab­ri­ela Staber Ap­poin­ted Part­ner...
    18/05/2018
    EU Product Li­ab­il­ity Dir­ect­ive still an ad­equate tool, ac­cord­ing to...
    On 7 May 2018, the European Com­mis­sion pub­lished its fifth re­port on the per­form­ance of the EU Product Li­ab­il­ity Dir­ect­ive (Dir­ect­ive/85/374/EEC) in the mem­ber states. The dir­ect­ive in­tro­duced the concept of strict li­ab­il­ity for pro­du­cers of de­fect­ive products.
    Christoph Wolf
    01/01/2018
    Good medi­cine in­stead of bit­ter pills
    Bro­chure Med­ic­al Law
    17/04/2018
    NGOs can ask the Com­mis­sion to re­view its de­cision on ge­net­ic­ally...
    The Gen­er­al Court de­cided in its de­cision of 14 March 2018 that non-gov­ern­ment­al or­gan­iz­a­tions (“NGOs”) can ask the Com­mis­sion to re­view its de­cision on au­thor­iz­ing the pla­cing on the mar­ket of ge­net­ic­ally mod­i­fied food and feed.
    01/01/2018
    For a healthy pro­spect
    Bro­chure Lifes­ci­ences
    25/01/2018
    European Com­mis­sion as­sesses ad­equacy of Gen­er­al Food Law in food...
    In an eval­u­ation of the EU le­gis­lat­ive frame­work for the 2002 Gen­er­al Food Law Reg­u­la­tion (GFLR), the European Com­mis­sion has found that this frame­work ap­pears to ad­dress most cur­rent trends, such as growth, com­pet­it­ive­ness and in­creased glob­al­isa­tion, but.
    10/08/2016
    Passing on pa­tient in­form­a­tion to law en­force­ment au­thor­it­ies
    Ärzte Krone
    28/11/2017
    REACH and Brexit – Some clar­ity gained but more cer­tainty re­quired
    Sev­en­teen months after the UK Ref­er­en­dum on wheth­er to re­main in or leave the EU a num­ber of areas re­main un­cer­tain for busi­ness.   For the chem­ic­als in­dustry[i] whose products form an in­teg­ral part of our daily lives, the status of the corner­stone of the chem­ic­als.
    27/07/2016
    Ad­miss­ib­il­ity of ad­vert­ising on the in­ter­net – Part...
    Uni­ver­sum In­nere Med­iz­in
    06/11/2017
    Brexit: State of play for Life Sci­ences com­pan­ies
    With the UK pre­par­ing to leave the European Uni­on (EU) on 30 March 2019, life sci­ences com­pan­ies are plan­ning ahead for changes to the busi­ness and reg­u­lat­ory en­vir­on­ment. Dis­cus­sions at the EU Sum­mit on 19 Oc­to­ber 2017 primar­ily fo­cused on what are re­garded.